Does UnitedHealthcare cover Zepbound? Yes, in two situations. Plans whose employer has chosen to cover weight-loss drugs cover Zepbound with prior authorization.[1] For plans that exclude weight-loss drugs, UnitedHealthcare has a separate sleep apnea-only policy that covers Zepbound for moderate to severe obstructive sleep apnea, with strict criteria.[2] Outside those routes, UHC says weight-loss drugs are “typically a benefit exclusion.”[2]
Prices and program terms checked October 2026. They change often; confirm with the manufacturer or your plan.
Zepbound is tirzepatide; see our tirzepatide profile.
UnitedHealthcare and Optum Rx
UnitedHealthcare’s pharmacy benefits are managed by Optum Rx, its sister company. UHC publishes the clinical criteria, and Optum Rx handles prescriptions and prior authorization requests. Your employer’s plan design decides whether weight-loss drugs are a covered benefit.[1]
Coverage by reason for treatment
| Reason prescribed | UHC commercial | UHC Medicare | UHC Community Plan (Medicaid) |
|---|---|---|---|
| Weight management | Only if the plan elects weight-loss coverage; prior authorization[1] | Not covered by Part D; Medicare GLP-1 Bridge for the KwikPen at $50 a month, if eligible[6] | Varies by state; Massachusetts ended it July 1, 2026[3] |
| Obstructive sleep apnea | Sleep apnea-only policy for plans that exclude weight loss[2] | Part D coverage under plan rules[7] | Covered in Massachusetts with prior authorization[3] |
| Type 2 diabetes | Not a Zepbound use; Mounjaro is the diabetes brand[4] | Mounjaro through Part D | Mounjaro, per state rules |
Weight-loss criteria (plans that cover weight-loss drugs)
UHC’s 2026 weight-loss drug program (2026 P 1114-23, effective October 1, 2026) is “an optional program” for clients that elect to cover weight-loss products.[1] For Zepbound it requires:[1]
- Treatment for weight loss, or for moderate to severe obstructive sleep apnea.
- Use alongside lifestyle changes such as diet, exercise, behavioral support or a community program.
- A BMI of 30 or more, or a BMI of 27 or more with a weight-related condition such as high cholesterol, high blood pressure, type 2 diabetes or sleep apnea.
Initial approval: 6 months.[1]
Renewal (12 months): at least 5% loss of starting body weight plus continued lifestyle changes. If you have been on Zepbound for six months or less and have not yet reached a maintenance dose, UHC allows a one-time 6-month extension.[1]
Sleep apnea-only criteria (plans that exclude weight loss)
Zepbound gained FDA approval for moderate to severe obstructive sleep apnea in adults with obesity on December 20, 2024.[5] UHC’s non-formulary Zepbound sleep apnea policy (2026 P 1475-3, effective September 1, 2026) requires all of the following:[2]
- Age 18 or older and a BMI of 30 or more.
- A sleep study showing an apnea-hypopnea index, respiratory event index or respiratory disturbance index above 15 events per hour.
- At least one earlier unsuccessful diet attempt.
- Either continued OSA symptoms despite using CPAP or another positive airway pressure device (at least 4 hours a night on 70% of nights), or a reason you cannot use one.
- No diabetes diagnosis and an HbA1c no higher than 6.5%.
- Counseling on sleep position and on avoiding alcohol or sedatives before bed.
- No planned sleep apnea or obesity surgery, and no predominantly central or mixed sleep apnea.
- A prescriber who is a sleep specialist, lung specialist or ear, nose and throat doctor, or who is experienced in managing OSA.
Initial approval: 6 months. Renewal: records showing your sleep test numbers improved from baseline after starting Zepbound.[2] See Zepbound for sleep apnea.
UnitedHealthcare Medicare
Medicare Part D excludes drugs used only for weight loss. For UHC’s Medicare Advantage and Part D plans:
- Sleep apnea: CMS says Zepbound prescribed for moderate to severe OSA stays under Part D, under the plan’s formulary and exception rules.[7]
- Weight management: since July 1, 2026, eligible members of most Part D and Medicare Advantage drug plans can get the Zepbound KwikPen for $50 a month through the CMS-run Medicare GLP-1 Bridge. Vials and single-dose pens are not covered.[6]
See does Medicare cover Zepbound?
UnitedHealthcare Community Plan (Medicaid)
Medicaid coverage depends on the state. In Massachusetts, UHC Community Plan stopped covering drugs used for weight loss and obesity, including Zepbound, on July 1, 2026. Zepbound stays covered there for conditions Medicare covers, such as obstructive sleep apnea, with prior authorization.[3]
Weight-loss policy vs sleep apnea-only policy
Which UHC policy applies depends on your plan, not on your choice:
- If your employer elected weight-loss coverage, the broader weight-loss program applies. It accepts either weight loss or OSA as the reason, uses label-style BMI rules (30, or 27 with a related condition) and does not require CPAP history or a specialist.[1]
- If your plan excludes weight-loss drugs, Zepbound is non-formulary, and the only path is the stricter OSA-only policy, which adds CPAP history, a diabetes exclusion and a sleep specialist.[2]
The weight-loss policy’s footnotes send plans without weight-loss coverage to the non-formulary Zepbound criteria, so a weight-loss request on such a plan is likely to be denied as a benefit exclusion.[1] If you are not sure which applies, ask member services to name the policy number used for your plan.
How to check your UHC coverage
- Sign in to myUHC or the Optum Rx app and search for Zepbound. Look for its tier and any PA (prior authorization) or quantity limit notes.
- Call the member services number on your UHC card. Ask: “Does my plan cover weight-loss drugs? If not, does the Zepbound sleep apnea policy apply?”
- Gather your records: BMI history, weight-related conditions, sleep study report, CPAP use data and diet history.
- Have your prescriber submit prior authorization through Optum Rx.
If UnitedHealthcare denies Zepbound
- Weight loss excluded: if you have OSA, ask your prescriber about the sleep apnea-only policy.[2]
- Sleep apnea denial: check for missing items, such as CPAP adherence data or a specialist’s involvement.
- Renewal denial: confirm the 5% weight-loss figure was measured from your starting weight.[1]
Paying if UHC won’t cover it
With commercial insurance that excludes Zepbound, Lilly’s savings card can lower the single-dose pen to as low as $499 a month or the KwikPen to $299 to $449.[8] LillyDirect sells vials and KwikPens for $299 to $449 a month to self-pay patients.[9] See Zepbound savings card, Zepbound cost without insurance and does insurance cover Zepbound?
